Starling Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Starling Oncology, Inc. (DFPH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price of $2.34 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $2.34.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $2.34.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $2.22.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $2.10.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $2.34 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.34 10-Q · filed 2026-05-07 |
| 2025-09-30 | $2.22 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.10 10-Q · filed 2026-08-06 |
| 2025-03-31 | $1.57 10-Q · filed 2026-05-07 |
| 2024-09-30 | $1.51 10-Q · filed 2025-11-13 |
| 2023-09-30 | $1.32 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.36 10-Q · filed 2023-08-09 |
| 2022-09-30 | $0.87 10-Q · filed 2023-11-08 |
| 2022-06-30 | $0.87 10-Q · filed 2023-08-09 |